MMEDHealthcare · Medical Instruments & Supplies

MMED Stock Forecast: MiniMed Group, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$16
−1.54% on the day

The 16 Wall Street analysts covering MiniMed Group, Inc. hold a median 12-month price target of $27 — +68.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 1 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.6B
Ticker Nerd rank
1/ 100
Median analyst target
$27
Analysts covering
16
Revenue$843.0M
Operating income$2.0M
Net income$0.0
Free cash flow−$90.0M
Quarterly, 6 quarters to 31 July 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.0%
1M
−8.5%
From high
−32.8%
From low
+48.2%
$11
$24
Range since 6 Mar 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores MiniMed Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
1/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
48
Issuance
11
Growth
10
Value
10
Momentum
7
Accruals
5
Volatility
3
Quality
1

Revisions (48): Analysts have, on balance, been raising their forecasts.

Quality (1): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MMED stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MMED, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 6 Mar 2026Adjusted close, US dollars
$10$15$20$25$30Apr 26Jul 26Oct 26MMEDHigh $30Median $27Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
12
Buy
3
Hold
1
Sell
$15
Low
$27
Median
$30
High

The green dot is the last close — the median target sits +68.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
13 Nov 2026BarclaysMaintainsEqual-Weight$22 → $20
12 Oct 2026JefferiesInitiatesHold$22
8 Oct 2026MizuhoMaintainsOutperform$26 → $28
7 Oct 2026BarclaysInitiatesEqual-Weight$22
24 Sept 2026Truist SecuritiesInitiatesBuy$29
3 Sept 2026Morgan StanleyMaintainsOverweight$19 → $21
2 Sept 2026B of A SecuritiesMaintainsBuy$24 → $28
2 Sept 2026CitigroupMaintainsBuy$23 → $26
2 Sept 2026Evercore ISI GroupMaintainsOutperform$20 → $27
2 Sept 2026MizuhoMaintainsOutperform$21 → $26
2 Sept 2026UBSMaintainsBuy$25 → $28
2 Sept 2026Wells FargoMaintainsOverweight$22 → $26
1 Sept 2026BTIGMaintainsBuy$25 → $28
28 July 2026UBSAssumesBuy$25
4 June 2026Wells FargoMaintainsOverweight$26 → $22
18 May 2026B of A SecuritiesMaintainsBuy—
12 May 2026BenchmarkInitiatesBuy—
1 Apr 2026BarclaysInitiatesOverweight—
31 Mar 2026B of A SecuritiesInitiatesBuy—
31 Mar 2026BTIGInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MMED.

Market Radar

This page is one stock. Monday covers all of them.

MMED appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MMED vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

MMED vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Apr 26Jul 26Oct 26MMEDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MMED analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+12.7%
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.4×

Cheaper than 57% of US stocks

Price / book
1.3×

Cheaper than 62% of US stocks

EV / EBITDA
15.5×

Cheaper than 32% of US stocks

Growth & margins
Revenue growth (YoY)
16.6%

Higher than 65% of US stocks

Earnings growth (YoY)
—
Gross margin
55.2%

Higher than 68% of US stocks

Operating margin
4.0%

Higher than 50% of US stocks

Net margin
−9.7%

Higher than 21% of US stocks

Returns & dividend
Return on equity
−8.7%

Higher than 37% of US stocks

Return on assets
−7.2%

Higher than 29% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MiniMed Group, Inc. has a market value of $4.6B and an enterprise value of $4.4B.

  • Revenue in the twelve months to 31 July 2026: $3.2B.

  • Net income over the same four quarters: −$326.0M, a −10.1% net margin.

  • Free cash flow in the twelve months to 31 July 2026: −$316.0M.

  • Shares outstanding: 281.2M.

  • forward P/E: 22.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • MiniMed Group, Inc. employs 8,000 people — $403K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 July 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

MMED and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
MMEDMiniMed Group, Inc.$4.6B1
STVNStevanato Group SpA$4.3B59
ICUIICU Medical, Inc.$4.3B95
MMSIMerit Medical Systems, Inc.$5.0B86
NVSTEnvista Holdings Corp.$3.7B96
PLSEPulse Biosciences, Inc.$3.3B54
TFXTeleflex, Inc.$6.4B93

Take a look at MMED’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own MiniMed Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about MMED

What is the MMED stock price forecast for 2026-2027?

The 16 Wall Street analysts covering MiniMed Group, Inc. have a median 12-month price target of $27, with estimates ranging from $15 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MMED stock a buy right now?

Of the 16 analysts covering MiniMed Group, Inc., 12 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks MiniMed Group, Inc. 1 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MMED?

As at 21 Nov 2026, MiniMed Group, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (48 of 100).

Will MMED stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +68.6% from the last close, and Ticker Nerd's factor model ranks MiniMed Group, Inc. 1 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MMED stock forecast for 2030?

No analyst covering MiniMed Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MMED are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $30 over the next 12 months.

What does MiniMed Group, Inc. do?

MiniMed Group, Inc. is a medical technology company focused on diabetes management. MiniMed develops, manufactures, and markets a connected ecosystem of products and services that includes insulin pumps, continuous glucose monitors, smart insulin pens, consumables, and supporting software.

Company

About MiniMed Group, Inc.

MiniMed Group, Inc. is a medical technology company focused on diabetes management. MiniMed develops, manufactures, and markets a connected ecosystem of products and services that includes insulin pumps, continuous glucose monitors, smart insulin pens, consumables, and supporting software. Its offerings are designed for people with type 1 diabetes and insulin-requiring type 2 diabetes, serving individual users, healthcare providers, distributors, and other institutions. The company’s portfolio centers on automated insulin delivery systems and smart multiple daily injection solutions, combining hardware, sensing technology, dosing algorithms, and digital health tools. Headquartered in Northridge, California, MiniMed Group plays a significant role in the diabetes care market by providing integrated technologies that support insulin therapy and glucose management.

CEO Ms. Que Thanh Dallara · 8,000 employees · United States · https://www.minimed.com